GSK放弃艾滋病药品部门上市计划

GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the next three years as the struggling UK pharmaceuticals group set out its strategy to revive growth.

葛兰素史克(GlaxoSmithKline，简称GSK)已放弃了转让部分艾滋病(HIV)药物部门的计划，并承诺要在今后三年内保证其稳定分红。这家深陷困境的英国制药集团正要着手实施其重获增长的战略。

The u-turn on a proposed multibillion-pound initial public offering of the ViiV Healthcare unit was the biggest surprise in a closely-watched presentation by Sir Andrew Witty, chief executive, aimed at shoring up investor confidence in the company and his leadership.

这个拟议中的ViiV Healthcare部门的首次公开招股(IPO)交易规模达数十亿英镑。安德鲁•维迪爵士(Sir Andrew Witty)的讲话中最令人震惊的一幕，就是该交易出现180度大转弯。这一讲话旨在提升投资者对GSK前景及安德鲁爵士领导力的信心，广受密切关注。

Sir Andrew floated the idea of a flotation for ViiV last year as a way to unlock value for GSK shareholders in what would have been among the biggest UK IPOs on record. He said on Wednesday it made more sense to keep the business because its growth prospects were stronger than anticipated.

安德鲁爵士去年提出了将ViiV部门挂牌上市的想法，并把它作为GSK股东解放其股票价值的途径。该交易原本可能成为英国有记录以来规模最大的IPO之一。周三，安德鲁爵士表示，由于该部门增长前景强于预期，将该部门留在GSK集团内更有意义。

The decision came as he set out his plans for turning GSK round after a period of falling sales for its crucial respiratory drugs in the US and a bruising corruption scandal in China.

公布这一决策之际，安德鲁爵士正着手实施重振GSK的计划。此前一段时期内，该公司不仅至关重要的呼吸系统药物在美国销量不断下滑，还在中国卷入了令它灰头土脸的腐败丑闻。

Earnings were forecast to drop by a high-teens percentage this year — more than analysts had expected — but Sir Andrew said growth would return next year and rise by a compound annual rate in the mid-to-high single digits between 2016 and 2020.

今年该公司盈利的下跌幅度预计会在16%到19%之间，高于分析师的预期。不过，安德鲁爵士表示明年该公司就会恢复增长，2016年到2020年该公司复合年增长率将在5%到9%之间。